Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serigne Lo

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyHelen Dearden, Lewis Au, Daniel Y Wang, et al.
Journal of the American Society of Nephrology : JASN|February 3, 2017
A Trial of Extending Hemodialysis Hours and Quality of LifeMeg J Jardine, Li Zuo, Nicholas A Gray, et al.
Brazilian Journal of Physical Therapy|August 20, 2020
The RESOLVE Trial for people with chronic low back pain: statistical analysis planMatthew K Bagg, Serigne Lo, Aidan G Cashin, et al.
British Journal of Cancer|May 20, 2017
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastasesSagun Parakh, John J Park, Shehara Mendis, et al.
Pigment Cell & Melanoma Research|October 7, 2019
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanomaRobert Mason, Helen C Dearden, Bella Nguyen, et al.
Circulation. Cardiovascular Quality and Outcomes|March 13, 2014
Hospital quality improvement initiative for patients with acute coronary syndromes in China: a cluster randomized, controlled trialXin Du, Runlin Gao, Fiona Turnbull, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapyGrace Heloise Attrill, Carina N Owen, Tasnia Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2017
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in MelanomaRicardo E Vilain, Alexander M Menzies, James S Wilmott, et al.
Contemporary Clinical Trials|May 27, 2018
The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviorsAmelia K Smit, Ainsley J Newson, Rachael L Morton, et al.
BMJ Open|October 15, 2015
Understanding burn injuries in Aboriginal and Torres Strait Islander children: protocol for a prospective cohort studyRebecca Q Ivers, Kate Hunter, Kathleen Clapham, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyHelen Dearden, Lewis Au, Daniel Y Wang, et al.
Journal of the American Society of Nephrology : JASN|February 3, 2017
A Trial of Extending Hemodialysis Hours and Quality of LifeMeg J Jardine, Li Zuo, Nicholas A Gray, et al.
Brazilian Journal of Physical Therapy|August 20, 2020
The RESOLVE Trial for people with chronic low back pain: statistical analysis planMatthew K Bagg, Serigne Lo, Aidan G Cashin, et al.
British Journal of Cancer|May 20, 2017
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastasesSagun Parakh, John J Park, Shehara Mendis, et al.
Pigment Cell & Melanoma Research|October 7, 2019
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanomaRobert Mason, Helen C Dearden, Bella Nguyen, et al.
Circulation. Cardiovascular Quality and Outcomes|March 13, 2014
Hospital quality improvement initiative for patients with acute coronary syndromes in China: a cluster randomized, controlled trialXin Du, Runlin Gao, Fiona Turnbull, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapyGrace Heloise Attrill, Carina N Owen, Tasnia Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2017
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in MelanomaRicardo E Vilain, Alexander M Menzies, James S Wilmott, et al.
Contemporary Clinical Trials|May 27, 2018
The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviorsAmelia K Smit, Ainsley J Newson, Rachael L Morton, et al.
BMJ Open|October 15, 2015
Understanding burn injuries in Aboriginal and Torres Strait Islander children: protocol for a prospective cohort studyRebecca Q Ivers, Kate Hunter, Kathleen Clapham, et al.
Pageof 11